Joint Development of ATL-DC-101
First written in FY2018-Q2. 2 of 5 entries say "Advanced", first in FY2019. Latest entry: FY2020-Q2.
No other company in this theme has enough history to compare yet.
- FY2020-Q2DroppedAnnual report
「In January 2020, we announced that we would discontinue the joint development and mutually terminate the joint development agreement.」
Discontinued joint development of ATL-DC-101 with the National Hospital Organization and mutually terminated the joint development agreement. - FY2020-Q1AdvancedAnnual report
「During the cumulative first-quarter period, we transferred manufacturing of the investigational product for the Phase II trial to the Shinagawa Cell Processing Facility and confirmed its comparability with the investigational product used in the Phase I trial.」
For ATL-DC-101, completed the transfer of manufacturing of the investigational product for the Phase II trial to the Shinagawa CPF and confirmed its comparability with the Phase I trial product. Meanwhile, due to delays in development, we have also begun reconsidering our future strategy. - FY2019AdvancedAnnual report
「During the current fiscal year, we transferred manufacturing of the investigational product for the Phase II trial to our Shinagawa Cell Processing Facility and are evaluating its comparability with the investigational product used in the Phase I trial. After confirming comparability, we plan to begin the Phase II trial jointly with the National Hospital Organization.」
For ATL-DC-101, transferred manufacturing of the investigational product for the Phase II trial to the Shinagawa CPF and advanced to the stage of beginning the Phase II trial after confirming comparability with the Phase I trial product. - FY2018-Q3RestatedAnnual report
「We will begin clinical trials during 2018 jointly with the National Hospital Organization and continue development targeting marketing approval in 2021.」
For ATL-DC-101, continued joint development with the National Hospital Organization, the start of clinical trials during 2018 and the target of obtaining approval in 2021. - FY2018-Q2First statedAnnual report
「We entered into a joint development agreement with the National Hospital Organization to obtain marketing approval for ATL-DC-101, a dendritic cell vaccine for adult T-cell leukemia, as a regenerative medical product, and will pursue development jointly with the National Hospital Organization with the aim of obtaining marketing approval in 2021.」
The Company signed a joint development agreement with the National Hospital Organization and began pursuing marketing approval for ATL-DC-101 in 2021.